Hepatitis C among drug users: consensus guidelines on management in general practice

  • Dublin Area Hepatitis C Initiative Group
  • Walter Cullen
Original Paper



Hepatitis C (HCV) is a common cause of morbidity among patients who attend general practitioners (GPs) in Ireland for methadone maintenance treatment.


To describe the development and content of guidelines for the management of HCV among current or former opiate users in the Eastern Regional Health Authority area attending GPs for methadone treatment.


The guidelines were produced in five stages: identification of key stakeholders; development of evidence-based draft guidelines; discussion of content; determination of ‘Delphi’-facilitated consensus and review by a sample of GPs for whom the guidelines would be intended.


The guidelines contain advice for GPs on all aspects of care of patients at risk of HCV, including general and preventative care, care of other bloodborne and hepatotoxic viruses, and the factors to be considered and appropriate evaluation prior to referring a patient for assessment at a hepatology unit.


GPs have an important role to play in the care of patients at risk of, or Infected with, HCV.


  1. 1.
    Allwright S, Bradley F, Long J et al. Prevalence of antibodies to hepatitis B, hepatitis C and HIV among Irish prisoners: results of a national cross sectional survey.Br Med J 2000; 321: 78–82.CrossRefGoogle Scholar
  2. 2.
    Smyth R, Keenan E, O’Connor J. Bloodborne viral infection in Irish injecting drug users.Addiction 1998; 93 (11): 1649–56.CrossRefPubMedGoogle Scholar
  3. 3.
    Prevalence of HCV among drug users attending general practice. Association of University Departments of General Practice Annual Scientific Meeting; 2000 July; Bournemouth.Google Scholar
  4. 4.
    Wong J, McQuillan G, McHutchinson J, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States.Am J Pub Health 2000; 90 (10): 1562–9.CrossRefGoogle Scholar
  5. 5.
    Keenan E, Barry J. Managing drug misuse in general practice.Br Med J 1999; 319: 1497.Google Scholar
  6. 6.
    Woolf S, Grol R, Hutchinson A. Clinical guidelines: potential benefits limitations and harms of clinical guidelines.Br Med J 1999; 318: 527–30.Google Scholar
  7. 7.
    Gerlach FM, Beyer M, Berndt M et al. [The DEGAM-concept-development, dissemination, implementation and evaluation of guidelines for general practice].Z Arztl Fortbild Qualitatssich 1999; 93 (2): 111–20.PubMedGoogle Scholar
  8. 8.
    Desirable attributes of clinical practice guidelines. Washington: Institute of Medicine. National Academy Press, 1992.Google Scholar
  9. 9.
    Conroy M, Shannon W. Clinical guidelines: their implementation in general practice.Br J Gen Prac 1995; 45 (396): 371–5.Google Scholar
  10. 10.
    Onion CW, Dutton CE, Walley T, Turnbull CJ, Dunne WT, Buchan IE. Local clinical guidelines: description and evaluation of a participative method for their development and implementation.Fam Pract 1996; 13(1): 28–34.CrossRefPubMedGoogle Scholar
  11. 11.
    Jones J, Hunter D. Consensus methods for medical and health services research.Br Med J 1995; 311: 376–80.Google Scholar
  12. 12.
    Broomfield D, Humphris G. Using the Delphi technique to identify cancer education requirements of general practitioners.Med Edu 2001; 35 (10): 928–37.Google Scholar
  13. 13.
    Guidelines on the management of hepatitis C in general practice: a semiqualitative interview survey of GPs’ views regarding content and implementation. Joint Symposium of the Society for the Study of Addiction and the Faculty of Substance Misuse of the Royal College of Psychiatrists; 2002; Leeds, UKGoogle Scholar
  14. 14.
    MacDonald M, Wodak. Preventing transmission of hepatitis C.Australian Fam Phys 1999; 28 (Special Issue 15): 14–7.Google Scholar
  15. 15.
    Management of hepatitis C.NIH Consensus Statement 1997; 15 (3): In press.Google Scholar
  16. 16.
    MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors.Epidem Rev 1996; 18 (2): 137–48.Google Scholar
  17. 17.
    Dienstag J. Sexual and perinatal transmission of hepatitis C.Hepatology 1997; 26 (Supplement 1): S66-S70.CrossRefGoogle Scholar
  18. 18.
    Consensus Statement. International Consensus Conference on hepatitis C; 1999 26–28 February; Paris. European Association for the Study of Liver Disease (EASL).Google Scholar
  19. 19.
    Sherman M. Management of viral hepatitis: clinical and public health perspectives — a consensus statement. CASL Hepatitis Consensus Group. Canadian Association for Study of the Liver.Can J Gastro 1997; 11 (5): 407–16.Google Scholar
  20. 20.
    Ohto H, Terazawa S, Sasaki N, Hino K, Ishiwata C et al. Transmission of hepatitis C from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group.New Engl J Med 1994; 330: 744–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Zanetti A, Tanzi E, Romano L et al. A prospective study on mother to infant transmission of hepatitis C virus. Intervirology 1998; 41: 208–12.CrossRefPubMedGoogle Scholar
  22. 22.
    Meisel H, Reip A, Faltus B et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin.Lancet 1995; 345: 1209–11.CrossRefPubMedGoogle Scholar
  23. 23.
    Thomas D, Villano S, Riester K et al. Perinatal transmission of hepatitis C virus from HIV-1 infected mothers. Women and Infants Transmission Study.J Infet Dis 1998; 177: 1480–8.CrossRefGoogle Scholar
  24. 24.
    Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease.Morbidity and Mortality Weekly Reports (MMWR): 1998: 1–39.Google Scholar
  25. 25.
    A strategy for the detection and management of hepatitis C in Australia. Canberra: National Health and Medical Research Council (NHMRC). Australian Government Publishing Service, 1997.Google Scholar
  26. 26.
    Garcia-Samaniego J, Soriano V, Castilla J. Influence of hepatitis C virus genotypes on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group.Am J Gastroentol 1997; 92: 1130–4.Google Scholar
  27. 27.
    Acharaya S, Dasarathy S, Kumer T et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome.Hepatology 1996; 23 (6): 1447–55.Google Scholar
  28. 28.
    Fong T, Di Bisceglie A, Waggoner J, Banks S, Hoofnagle J. The significance of antibody to hepatitis C in patients with chronic hepatitis C.Hepatology 1991; 14: 64–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Chiaramonte M, Stroffolini T, Vian A. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.Cancer 1999; 85: 2132–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Keating S. Vaccination guidelines for patients attending the ERHA drug treatment clinics. Dublin: Eastern Regional Health Authority, 2000.Google Scholar
  31. 31.
    Immunisation guidelines for Ireland: National Immunisation Committee, Royal College of Physicians of Ireland, 1999.Google Scholar
  32. 32.
    Immunological responses to hepatitis C and non-hepatitis C antigens in hepatitis C (HCV) and human immunodeficiency (HIV)-HCV coinfected patients. XIII International AIDS Conference; 2000; Durban, South Africa.Google Scholar
  33. 33.
    Melvin D, Lee J, Belsey E. The impact of co-infection with hepatitis C and HIV on the tolerability of antiretroviral therapy.AIDS Patient Care STDS 2000; 14: 463–85.Google Scholar
  34. 34.
    Poles M, Dieterich D. Hepatitis C Virus/Human immunodeficiency virus coinfection: clinical management issues.Clin Infect Dis 2000; 31 (1): 154–61.CrossRefPubMedGoogle Scholar
  35. 35.
    Furner V, Ross M. Lifestyle clues in the recognition of HIV infection.Med J Aust 1993; 158: 40–1.PubMedGoogle Scholar
  36. 36.
    Carne P, Roass M, Kemp R. A practitioner’s guide to HIV testing.Medical Journal of Australia 1993; 158: 267–8.PubMedGoogle Scholar
  37. 37.
    Kidd M, Cheng W, Wilson S. Initial management of hepatitis C.Aust Fam Phys 1999; 28: SI32–35.Google Scholar
  38. 38.
    McCoy R, Watson K, Kosky M. A guide to diagnosis.Aust Fam Phys 1999; 28: SI19-SI23.Google Scholar
  39. 39.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups.Lancet 1997; 349(9055): 825–32.CrossRefPubMedGoogle Scholar
  40. 40.
    Schiff E. Hepatitis C and alcohol.Hepatology 1997; 26 (3 Suppl 1): 39S-42S.CrossRefPubMedGoogle Scholar
  41. 41.
    Harley H, Shaw D, Steven I. Ongoing management of hepatitis C.Australian Fam Phys 1999; 28 (Special Issue): SI36–9.Google Scholar
  42. 42.
    Ortiz V, Berenguer M, Rayon J, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression.Am J Gastroenterol 2002; 97: 2408–14.CrossRefPubMedGoogle Scholar
  43. 43.
    Lam N, Pitrak D, Speralakis R et al. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.Dig Dis Sci 1997; 42: 178–85.CrossRefPubMedGoogle Scholar
  44. 44.
    Davis G, Lau J, Urdea M, et al. Quantitative detection of hepatitis C virus RNA with a solid phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients.Hepatology 1994; 19: 1337–41.CrossRefPubMedGoogle Scholar
  45. 45.
    Best D, Lehman P, Gossop M et al. Eating too little, smoking and drinking too much: wider lifestyle problems among methadone maintenance patients.Addiction 1998; 6: 290–1.Google Scholar
  46. 46.
    RACGP/ANCARD Hepatitis C algorithms.Aust Fam Phys 1999; 28 (SI 71): 72–7.Google Scholar

Copyright information

© Springer 2004

Authors and Affiliations

  • Dublin Area Hepatitis C Initiative Group
  • Walter Cullen
    • 1
  1. 1.Department of General PracticeUniversity College Dublin, Coombe Healthcare CentreDublin 8Ireland

Personalised recommendations